Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration

American Journal of Ophthalmology

Volumn 156, Issue 1, 2013, Pages

  Schachat, Andrew P ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

CENTRAL MACULAR THICKNESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL FLUID; TREATMENT OUTCOME; TREATMENT RESPONSE; VISION; VISUAL ACUITY;

EID: 84879228200     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.04.009     Document Type: Editorial

References (13)

1. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham, M. Feinsod, D.R. Guyer, and for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 27 2004 2805 2816
2. D.M. Brown, P.K. Kaiser, and M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444
3. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
4. J.S. Heier, D.M. Brown, and V. Chong Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 12 2012 2537 2548
5. Comparison of Age-Related Macular Degeneration Treatments Trials Research Group, D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Ophthalmology 119 7 2012 1388 1398
6. IVAN Study Investigators, U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 8 2012 1508
7. C.D. Regillo, D.M. Brown, and P. Abraham Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1 Am J Ophthalmol 145 2 2008 239 248
8. Y. Yonekawa, C. Andreoli, and J.B. Miller Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration Am J Ophthalmol 156 1 2013 29 35
9. B. Bakall, J.C. Folk, and E.H. Sohn Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab Am J Ophthalmol 156 1 2013 15 22
10. V.Y. Ho, S. Yeh, and T.W. Olsen Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors Am J Ophthalmol 156 1 2013 23 28
11. J.M. Seddon, R. Reynolds, Y. Yu, M.J. Daly, and B. Rosner Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors Ophthalmology 118 11 2011 2203 2211
12. Age-Related Eye Disease Study Research Group A simplified severity scale for age-related macular degeneration AREDS report no. 18 Arch Ophthalmol 123 11 2005 1570 1574
13. Hagstrom SA, Ying G, Pauer GJT, et al. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology doi:10.1016/j.ophtha.2012.11.037. 2013.01.18.